Strategic partnerships Pursue collaboration opportunities with automation hardware leaders (eg Tecan) and contract manufacturers to accelerate denovoSkin production scale, reduce CAPEX, and shorten time-to-market for commercialized skin tissue therapies.

Clinical leadership Leverage ongoing Phase 3 trials and Orphan Drug Designations to engage with hospital systems, burn centers, reconstructive and aesthetic clinics, and payers seeking first-in-class regenerative solutions with favorable regulatory tailwinds.

Manufacturing automation Opportunity to position CUTISS as a turnkey biomanufacturing partner offering automated, scalable skin tissue production, appealing to biotech manufacturers and contract development and manufacturing organizations aiming to add personalized tissue products.

Global market readiness Target EU and US markets with reimbursement‑driven value propositions, highlighting denovoSkin’s potential to redefine standard of care in skin surgery and its alignment with regulatory designations to accelerate market access.

Investment and expansion Engage capital partners and strategic investors around continued Series C milestones and commercialization milestones, while offering visibility into scale-up plans, manufacturing partnerships, and revenue potential from a first‑in‑class therapy.